Racura Oncology

Company

Racura Oncology develops one asset, in phase 1 (RC220 in egfr-mutant non-small cell lung cancer). Mostly other.

1
Asset
Furthest stage
Phase 1
2
Trials
1
Signal

Pipeline

1
  • RC220

    Phase 1, Other, egfr-mutant non-small cell lung cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials2
  • Signals1

Intelligence